- Biosimilars name, notification debates rage on, but costs still 'elephant in the room'
- Pfizer promotes 'underappreciated' R&D pipeline
- Biosimilar Enbrel filed with EMA
- Novartis/Sandoz biosimilar 1st to win FDA panel backing
COMMENT Other Informa Comment
- Profile: Fred Hassan, pharma titan, gooseberry picker and secret geography geek
- INTERVIEW: Ding plans Betta chances for Conmana in China